Medical Mysteries: Years of hives and fevers traced to a startling cause
For 18 years a woman suffered from an episodic illness featuring hives and fevers that stumped doctors. The cause, discovered after surgery, was mind-blowing. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 13, 2024 Category: Consumer Health News Authors: Sandra G. Boodman Source Type: news
How Animals and Nature React to an Eclipse
Of all of the animals worth observing during a total solar eclipse, some of the most intriguing are humans. They stop what they’re doing; they stare skyward; they lower their voices to a hush. Some may gather their young close. Some may even shed tears. If you’ve ever witnessed a solar eclipse yourself, none of this comes as a surprise; indeed, you’ve surely exhibited some of these behaviors too. Other species of animals display other kinds of behavioral changes, as the weather and lighting and nature itself seem to turn on their axes. So what should you expect to experience on April 8, as a total eclipse...
Source: TIME: Science - March 25, 2024 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Eclipse Source Type: news
Puzzling skin side effects stymie advance of promising HIV vaccine
One of the most promising attempts to reinvigorate the stalled quest for an HIV vaccine has hit a snag that might seem minor but has major consequences: delaying the larger trials needed to show whether the concept works. In small safety and immune tests of the innovative vaccine strategy, which relies on a series of messenger RNA (mRNA) shots, an unusually high percentage of recipients developed rashes, welts, or other skin irritations.
“We are taking this very seriously,” says Carl Dieffenbach, who heads the Division of AIDS at the National Institute of Allergy and Infectious Diseases, which funded a recent pha...
Source: ScienceNOW - March 1, 2024 Category: Science Source Type: news
Novel Antibody for Chronic Hives Brings Relief in Mid-Stage Trial
(MedPage Today) -- WASHINGTON -- Barzolvolimab, a first-in-class anti-KIT monoclonal antibody, reduced the severity of hives in adults with chronic spontaneous urticaria (CSU) who remained symptomatic on antihistamines, a randomized phase II... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 29, 2024 Category: Allergy & Immunology Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
Xolair for food allergies: How it works and what it costs
Kevin Wang and Annie Marqueling’s son Liam was 8 months old when he broke out in hives all over his body after eating a few bits of a scrambled egg. An allergy test revealed Liam was allergic to eggs, as well as peanuts and tree nuts, and for the next year, the entire family avoided foods that…#kevinwang #anniemarquelings #wang #paloalto #xolair #sharonchinthrajah #stanforduniversity #chinthrajah #fda #annalsofallergy (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2024 Category: Consumer Health News Source Type: news
Asthma drug limits serious reactions to allergy-triggering foods, study says
A drug approved to treat allergic asthma and chronic hives can limit children ' s dangerous allergic responses to small amounts of allergy-triggering foods, a new study reveals. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 25, 2024 Category: Consumer Health News Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Japan First in the World to Approve Dupixent ® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron…#dupixent #csu #ny #sanofi #welfare #regeneron #eoe #velocimmune #georgedyancopoulos #frederickwalt (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2024 Category: Consumer Health News Source Type: news
Etiology Elusive in Nearly 40% Cases of Urticaria in Infants Etiology Elusive in Nearly 40% Cases of Urticaria in Infants
Symptoms are most likely to resolve spontaneously, researchers said.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 15, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
The King Of Cones: Inside The Cannabis Industry ’s $75 Million Pre-Roll Empire
Bryan Gerber’s Hara Supply produces more than 100 million cones a month for mainstream brands such as Jeeter and Zig-Zag in one of the fastest-growing segments of the marijuana market. hen Bryan Gerber grinds cannabis to roll a joint, he breaks out in hives. But that hasn’t stopped the 32-year-old…#bryangerbers #bryangerber #bhasin #henrykochhar #thaitran #harasupply #lasvegas #delhi #veranoholdings #swiftlifts (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2023 Category: Consumer Health News Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Media News - December 19, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Investor Update - December 19, 2023 Category: Pharmaceuticals Source Type: news
